Evidara for Medical Affairs

Walk into every KOL meeting
knowing more than they do.

Scientific exchange requires knowing the evidence your KOL already knows — and the gaps they'll probe. Evidara produces a complete scientific exchange brief in 20 minutes: mechanism, comparative effectiveness, safety profile, recent literature, and HTA context — fully sourced and compliant.

Request a Demo → Explore free →

20min

Scientific exchange brief — from query to structured, sourced evidence package

21 CFR

Part 11 audit trail on every analysis — compliant documentation for MSL activities

HIPAA

BAA available · PHI firewall blocks patient identifiers before processing

100%

Of evidence claims linked to PMID, NCT ID, or NDA — no unsourced assertions

The medical affairs preparation gap

Three days of preparation work
before every scientific exchange.

01 — KOL Meeting Preparation

Scientific exchange prep takes 3 days of MSL time

Walking into a KOL meeting prepared means knowing the evidence landscape in depth — including what the KOL has published, what their concerns are, and what data gaps they'll surface. That preparation typically takes 2–3 days per engagement, even for experienced MSLs.

~2–3 days MSL time per engagement

02 — Comparative Effectiveness Questions

HCPs ask about comparators you haven't fully prepared for

Healthcare providers ask comparative effectiveness questions that go beyond the clinical dossier — mechanism differences, real-world safety signals, head-to-head trial gaps, and payer evidence requirements. Answering credibly requires deep cross-database preparation.

Missed scientific exchange opportunities

03 — Compliance Documentation

Scientific exchange activities need auditable documentation

Every MSL scientific exchange requires documentation — what evidence was shared, what sources were cited, whether off-label information was appropriately flagged. Manual documentation is inconsistent. Regulators and legal expect an audit trail, not meeting notes.

Compliance risk without audit trail

How Evidara solves it

Evidence briefs that prepare your team
for every scientific conversation.

Protocol MSL — Scientific Exchange Brief

KOL briefing document in 20 minutes

Chain MSL produces a complete scientific exchange brief — drug and indication resolution, clinical evidence synthesis, safety profile, recent publications, competitive intelligence, and key messages with objection handlers — structured in the format MSLs use in pre-meeting preparation. Fully sourced. Export to PDF.

Mechanism and target rationale with pathway evidence

Comparative effectiveness vs. key comparators

Recent publications and trial data your KOL may know

Evidence gaps the KOL is likely to probe

Protocol C — Safety Intelligence

Real-world safety profile for HCP conversations

HCPs ask about safety signals beyond clinical trial data. Chain C queries FDA FAERS adverse event reports, published real-world safety literature, and drug label history — returning a structured safety profile aligned to what prescribers, payers, and KOLs actually ask about.

FAERS adverse event signals vs. comparators

Real-world safety literature — post-marketing studies

Label evolution and safety update history

SPARSE_DATA flags where evidence is limited

21 CFR Part 11 Audit Trail

Every scientific exchange fully documented

Every Evidara analysis generates a 21 CFR Part 11-compliant audit trail: agent identities, source provenance, input hash, output hash, user identity, and HMAC signature. The evidence basis for every scientific exchange activity is documented and auditable by construction — not by policy.

HMAC-signed audit row per analysis — tamper-evident

Source provenance on every evidence claim shared

User identity and timestamp on every output

INSERT-only audit log — cannot be modified retroactively

Illustrative example

KRAS G12C scientific exchange brief — run live

Chain MSL prepares a scientific exchange brief for an MSL ahead of a KOL meeting — combining target rationale, clinical trial evidence, the competitive landscape and post-marketing safety into anticipated questions with sourced answers.

Run this analysis yourself →

"Prepare a scientific exchange brief for a KRAS G12C KOL meeting — mechanism, clinical evidence, competitive landscape, and what the KOL is likely to ask about"

Target-directed compounds retrieved from ChEMBL, split by development stage

Congress abstracts and KOL publication record surfaced for the meeting attendee

Resistance mechanisms collated from the literature and raised as an anticipated question

Sotorasib vs. adagrasib: head-to-head trial absent — indirect comparison evidence only

FAERS post-marketing profile compared against the approved label

Chain MSL · Illustrative example — not a live run · PROVISIONAL, requires expert review

Walk into every KOL meetingknowing more than they do.

Three days of preparation workbefore every scientific exchange.

Evidence briefs that prepare your teamfor every scientific conversation.